IN8bio, Inc.
As of Oct 22, 2026, IN8bio is in Stage 1, the basing phase, now in week 2 (since Oct 14, 2026). It closed at $0.99, 61.9% below its 52-week high and below its 200-day average, which is falling.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INAB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INAB among Biotechnology369th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …369 | INAB | Stage 1 · wk 2 | 22 | −10.4% |
IN8bio: quick answers
What stage is IN8bio in?
As of Oct 22, 2026, IN8bio (INAB) is in Stage 1, the basing phase. It entered Stage 1 on Oct 14, 2026 and is in week 2. What the four stages mean
Is IN8bio in an uptrend?
Not yet. IN8bio is in Stage 1, a base that can come before an uptrend. It trades 34.0% below its 200-day average, which is falling.
How far is IN8bio from its 52-week high?
IN8bio closed at $0.99 on Oct 22, 2026, 61.9% below its 52-week high of $2.59. Its 52-week low is $0.96.
How has IN8bio performed over the past year?
As of Oct 22, 2026, IN8bio is down 52.8% over the past year and down 59.9% so far in 2026.
Which sector and industry is IN8bio in?
IN8bio is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.